Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections

被引:16
作者
Bulger, Eileen M. [1 ]
May, Addison [2 ]
Dankner, Wayne [3 ]
Maislin, Gregory [4 ]
Robinson, Bryce [1 ]
Shirvan, Anat [3 ]
机构
[1] Univ Washington, Dept Surg, Seattle, WA 98195 USA
[2] Vanderbilt Univ Sch Med, Dept Surg, Nashville, TN USA
[3] Atox Bio Ltd, Ness Ziona, Israel
[4] Biomed Stat Consulting, Philadelphia, PA USA
关键词
Necrotizing soft tissue infection; Fournier's gangrene; clinical trial; composite endpoint; HYPERBARIC-OXYGEN; INTRAVENOUS IMMUNOGLOBULIN; LETHAL SHOCK; MORTALITY; THERAPY; SEPSIS; SCORE; RISK;
D O I
10.1097/TA.0000000000001564
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
OBJECTIVE: Our objective was to develop and validate a composite endpoint for patients with necrotizing soft tissue infections that incorporates: local tissue injury, systemic organ dysfunction, and mortality. METHODS: The Necrotizing Infection Clinical Composite Endpoint (NICCE) was defined as follows:(i) alive at day 28, (ii) three or less debridements before day 14, (iii) no amputation beyond first debridement, (iv) modified sequential organ failure assessment score score (mSOFA) at day 14 <= 1. To be considered a success, all individual criteria must be met. Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (ii) a subset with high disease acuity, admission mSOFA score of 3 or higher (n = 69); and (iii) 40 patients from a multicenter, phase 2 randomized trial of a CD28 immunomodulator (AB103). Clinical success based on each parameter and the composite score was assessed. RESULTS: Using the retrospective data set for all patients and those with high disease severity (respectively), survival rates were 92% and 84%; day 14 mSOFA 1 or lower score was 69% and 51%; three or less debridements was 84% and 77%; and no subsequent amputations were 96% and 94%. Overall, the percent meeting all success criteria for NICCE was 58% (all patients) and 33% (mSOFA > 3). NICCE success was also associated with reduced utilization of health care resources, intensive care unit-free days were median (interquartile range) of 25.3 (21.9-28) and 19.6 (4.3-25.1) days (one-sided Wilcoxon p < 0.001) and ventilator-free days were 28 (26-28) versus 25 (14-28) (p < 0.001) for NICCE success versus failure, respectively. Using the phase 2 data set, the treated group (0.5 mg/kg, n = 15) demonstrated a NICCE success rate of 73.3% versus 40% for placebo (n = 10). CONCLUSION: These data demonstrate internal consistency of the components and face and criterion validity of the NICCE endpoint. NICCE offers an opportunity to demonstrate a clinically relevant treatment effect for patients enrolled in clinical trials for necrotizing soft tissue infection. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:622 / 627
页数:6
相关论文
共 23 条
[1]   Predictors of mortality and limb loss in necrotizing soft tissue infections [J].
Anaya, DA ;
McMahon, K ;
Nathens, AB ;
Sullivan, SR ;
Foy, H ;
Bulger, E .
ARCHIVES OF SURGERY, 2005, 140 (02) :151-157
[2]   Necrotizing soft-tissue infection: Diagnosis and management [J].
Anaya, Daniel A. ;
Dellinger, E. Patchen .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (05) :705-710
[3]   Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation [J].
Arad, G ;
Levy, R ;
Hillman, D ;
Kaempfer, R .
NATURE MEDICINE, 2000, 6 (04) :414-421
[4]   Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide [J].
Arad, G ;
Hillman, D ;
Levy, R ;
Kaempfer, R .
IMMUNOLOGY LETTERS, 2004, 91 (2-3) :141-145
[5]  
Arad G, 2001, J LEUKOCYTE BIOL, V69, P921
[6]   Binding of Superantigen Toxins into the CD28 Homodimer Interface Is Essential for Induction of Cytokine Genes That Mediate Lethal Shock [J].
Arad, Gila ;
Levy, Revital ;
Nasie, Iris ;
Hillman, Dalia ;
Rotfogel, Ziv ;
Barash, Uri ;
Supper, Emmanuelle ;
Shpilka, Tomer ;
Minis, Adi ;
Kaempfer, Raymond .
PLOS BIOLOGY, 2011, 9 (09)
[7]   Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management [J].
Boyer, Alexandre ;
Vargas, Frederic ;
Coste, Fanny ;
Saubusse, Elodie ;
Castaing, Yves ;
Gbikpi-Benissan, Georges ;
Hilbert, Gilles ;
Gruson, Didier .
INTENSIVE CARE MEDICINE, 2009, 35 (05) :847-853
[8]   Impact and Progression of Organ Dysfunction in Patients with Necrotizing Soft Tissue Infections: A Multicenter Study [J].
Bulger, Eileen M. ;
May, Addison ;
Bernard, Andrew ;
Cohn, Stephen ;
Evans, David C. ;
Henry, Sharon ;
Quick, Jacob ;
Kobayashi, Leslie ;
Foster, Kevin ;
Duane, Therese M. ;
Sawyer, Robert G. ;
Kellum, John A. ;
Maung, Adrian ;
Maislin, Greg ;
Smith, David D. ;
Segalovich, Irit ;
Dankner, Wayne ;
Shirvan, Anat .
SURGICAL INFECTIONS, 2015, 16 (06) :694-701
[9]   A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections A Randomized Clinical Trial [J].
Bulger, Eileen M. ;
Maier, Ronald V. ;
Sperry, Jason ;
Joshi, Manjari ;
Henry, Sharon ;
Moore, Frederick A. ;
Moldawer, Lyle L. ;
Demetriades, Demetrios ;
Talving, Peep ;
Schreiber, Martin ;
Ham, Bruce ;
Cohen, Mitchell ;
Opal, Steven ;
Segalovich, Irit ;
Maislin, Greg ;
Kaempfer, Raymond ;
Shirvan, Anat .
JAMA SURGERY, 2014, 149 (06) :528-536
[10]   Effectiveness of Clindamycin and Intravenous Immunoglobulin, and Risk of Disease in Contacts, in Invasive Group A Streptococcal Infections [J].
Carapetis, Jonathan R. ;
Jacoby, Peter ;
Carville, Kylie ;
Ang, Seong-Jin Joel ;
Curtis, Nigel ;
Andrews, Ross .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (03) :358-365